CureVac - bullish - Q1 - mid-termCureVac - bullish - Q1 - mid-term possbile route - many shares have the same formation right now.. with a more likely breakout on top
Medical
BNGO - Ready to go to Mars 🚀If it breaks the 13.29 Resistance point, goes to mars. All it needs is more good news (which come every week) and a good volume. Lets Go!
In search for the next NAKD Naked Brand? Volume play!Can you see some volume patterns?
This was my first NAKD Naked Brand post:
GBT Researching AI based, Robotics Technology for the Medical Field
GBT Researching a Development of a Radio Based Computer Vision System For Cardiovascular Applications
GBT Tokenize Corp Evaluating qTerm Applications for Hotel Industry
GBT Developing a Long-Range Radio System Targeting Global Communication for Remote Telemedicine (globenewswire.com)
AI Eye Podcast: GBT Technologies' CTO Discusses the Significance of FDA Approval for the qTerm Human Vital Signs Device. (newsfilecorp.com)
Fell free to Join my Patreon group in the description of this idea!
Teladoc close to resistance Teladoc is close to 253 resistance tested in Aug 2020. It's clearly bullish, but is there more to go?
Wait and see.
ONEM over 44.50Nice consolidation here, candle shadows seem to show sell pressure, which should lead to a bigger breakout.
867 China Medical Systems Breakout / Long IdeaHello Tradingviewians,
CMS has been in a long consolidation to digest lowering growth rates. Additionally it has been under fire by short sellers, alleging CMS of faking revenue numbers.
Should the numbers be genuine, and factors like consistent insider buying suggest it, CMS represents serious value at this point.
Technically, a two year downtrend collides with the support line of the superordinate uptrend. Should ladder win, a short squeeze may follow to previous interim highs. After a phase of returning confidence, all time highs could be reached again.
This is my first published technically supported investment idea.
Let me know what you think.
Thanks!
BR
LABU Long (Monthly)LABU Long analysis on the monthly. Looks like a lot of accumulation looking to breakout biggins.
Careplussupport level at 3.20
Resistance 1 : 3.50
Resistance 2 : 3.85
medical gloves are on demand globally so investing in careplus till 2021 shouldn’t be an issue. *Profitable company *
If you bought at the higher price my suggestion is use this formula call (buy on deep)
Buy On deep at 3.25
It’s helps you to lower your total unit price (Lower price vs more units in hand )
Careplus projection to 4rm in 2weeks time
( TRADE WHATS THE WORLD NEEDS)
Johnson and Johnson - JNJ top-down video AnalysisHello everyone, here is the top-down analysis for JNJ, feel free to request any pair/instrument or ask any questions in the comment section below.
Best of luck!
ACHV Achieve Life Sciences 10X potential! Highest undervalued!On 8/7/2020 Brokerage LADENBURG THALM/SH SH Reiterated ACHV Rating to BUY and set the target price to $100.00, now the cost of one share is 9.84usd. You can find the asset on trading212, the most downloaded trading app in the U.K.
With a market cap of $15.45 million and a worldwide working product, it`s hard to say ACHV can go lower than that. The only concern is how much upside potential does it have.
On July 31 ACHIEVE ANNOUNCES PATENT GRANTED IN THE U.S. FOR NOVEL ANALOGS OF CYTISINICLINE FOR USE IN CNS AND ADDICTION INDICATIONS.
Also Short Interest in Achieve Life Sciences Inc Drops By 81.1%.
Achieve Life Sciences issued its quarterly earnings results on Aug 4th. The biopharmaceutical company reported ($1.68) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($3.80) by $2.12, Fidelity Earnings reports.
If you are interested to test some amazing BUY and SELL INDICATORS, which give the signal at the beginning of the candle, not at the end of it, just leave me a message.
RVP Aroon Indicator entered an Uptrend on July 28, 2020Over the last three days, I have detected that RVP's AroonUp green line is above 70, while the AroonDown red line is below 30. When the green line goes above 70 while the red line stays below 30, this is an indicator that the stock could be poised for a strong Uptrend. For traders, this could mean going long the stock or exploring call options in the next month. I backtested this indicator and found 193 similar cases, 184 of which were successful. Based on this data, the odds of success are 90%.
Zynex medical technology Zynex, Inc., a medical technology company, designs, manufactures, and markets electrotherapy medical devices used for pain management and rehabilitation.
BIOL WWLooking for .48c entry
Tight stop below .45c support @ .44c
looking for PT1 .61c
RR 3.25
Risking 8.33%
for
Gains of 27.08%
PT2 .75c
Risking 8.33%
RR 6.75
Gains of 56.25%
PT3
Risking 8.33%
RR 8.5
Gains of 70.83%
NSPR EMA and Volume rockingThe market atm is pretty boring. Bitcoin is doing nothing, stocks trading on news, Tesla mooning on earnings epectations with possibility of NASDAQ listing, cruise lines crap, and tech stocks booming. Now I been watching NSPR a little trying to find a good time to buy. NSPR is a medical stock that helps certain surgeries possible, yet its downfall is its not sold in the USA and it might be awhile till it is.
TA
-looking at the hourly and even the daily you can see its at its highest volume since June 02 the dump from .81 to now and has been mainting this high volume.
-hourly emas look to be cloing in a bullish move, yet on the daily it does get rejected, so entering the trade on emas targets range are .55-.7
-MACD is uptrending up on the daily and hourly
-RSI is overbought on the hourly, yet neutral on the daily.
-Earning are coming up and the last two earnings don't show much. Last one sideways and the other one it dumped, but pumped higher later.
I personally took a gamble and bought 3k shares, yet would keep this one on your radar just cause the volume at the moment is unlike anything it has done in the past.
Quanterix Corporation (QTRX) short.All description on the chart.
Please, don't forget to like and follow.
Thank you.
ATEC enters Uptrend as Momentum indicator ascends above 0 levelThis indicator may be signaling that ATEC's price has momentum to move higher, since its current price exceeds the price logged 14 days ago. Traders may consider buying the stock or exploring call options. I backtested 96 similar cases where ATEC's Momentum Indicator exceeded 0, and 81 of them led to a successful outcome. Odds of Success: 84%.
CDNA MA MACD Histogram just turned positiveThis is a Bullish indicator signaling CDNA's price could rise from here. Traders may explore going long the stock or buying call options. I identified 45 similar cases where CDNA's MACD histogram became positive, and 34 of them led to successful outcomes. Odds of Success: 76%.
QUIDEL $QDEL "New High"$QDEL did a new high, RSI did too. Volume is far above the average.
12 months Consensus Price Target: $117
if you find my charts useful, please leave me "like" or "comment".
Please don't trade according to the ideas, rely on your own knowledge.
Thx
CERS MA MACD Histogram just turned positiveThis is a Bullish indicator signaling CERS's price could rise from here. Traders may explore going long the stock or buying call options. I identified 41 similar cases where CERS's MACD histogram became positive, and 34 of them led to successful outcomes. Odds of Success: 83%.
RVP was a top gainer,rising +442.61%.Expect Uptrend continuationRetractable Technologies (RVP, $6.24) was one of top quarterly gainers, jumping +442.61% to $6.24 per share. Tickeron A.I.dvisor analyzed 203 stocks in the Medical Specialties Industry over the last three months, and discovered that 191 of them (93.98%) charted an Uptrend while 12 of them (6.02%) trended down. Tickeron A.I.dvisor found 295 similar cases when RVP's price jumped over 15% within three months. In 154 out of those 295 cases, RVP's price went up during the following month. Based on these historical data, Tickeron A.I. thinks the odds of an Uptrend continuation for RVP are 52%.
iBio Chart UpdateAnother one of these "COVID Stocks" - Decisions, decisions upcoming - take it or leave it at this point.
Don't take as financial advice...
